ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4998ometendo-4998Research ArticleСтатьиArticlesАнтиатерогенные эффекты микронизированного фенофибрата при метаболическом синдроме и сахарном диабете 2 типаAntiaterogennye effekty mikronizirovannogo fenofibrata pri metabolicheskom sindrome i sakharnom diabete 2 tipaPerovaN V-20071512200744№4 (2007)27Copyright © Perova N.V., 20072007Perova N.V.Perova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4998ReferencesHaffner S.M., Reexamining the risks of coronary artery disease. Drug Benefit Trends. 2001;13 Supll A: S5-S14.Haffner S.M., Reexamining the risks of coronary artery disease. Drug Benefit Trends. 2001;13 Supll A: S5-S14.Reaven G.M. Role og insulin resistance in human disease. Diabetes. 1988;37:1595-1602.Reaven G.M. Role og insulin resistance in human disease. Diabetes. 1988;37:1595-1602.Donahue R.P., Orchard J. Hyperinsulinemia and insulin resistense associations with cardiovascular risk factors and disease. Cardiovasc Risk Factors. 1993;1:12-18.Donahue R.P., Orchard J. Hyperinsulinemia and insulin resistense associations with cardiovascular risk factors and disease. Cardiovasc Risk Factors. 1993;1:12-18.Vckeigue P.M. Epidemiology of the insulin resistence syndrome in South Asians and Europeans. Cardiovasc Risk Factors.1993;3:27-35.Vckeigue P.M. Epidemiology of the insulin resistence syndrome in South Asians and Europeans. Cardiovasc Risk Factors.1993;3:27-35.Adkins J.C., Faulds D. Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1995;54 (4):615-63.Adkins J.C., Faulds D. Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1995;54 (4):615-63.Fruchart J.C., Brewer H.B., Leitersdorf E. Consesus for use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol. 1998;81:912-916.Fruchart J.C., Brewer H.B., Leitersdorf E. Consesus for use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol. 1998;81:912-916.Batfour J.A., Mc.Tavish D., Heel R.C. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipilaemia. Druds. 1990;40:260-290.Batfour J.A., Mc.Tavish D., Heel R.C. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipilaemia. Druds. 1990;40:260-290.Erikson U., Hulmius G., Hemmingsson A. et al. Repeart femoral arteriography in hyperlipidemic patients, a study of progression and regression of atherosclerosis. Acta Radiol. 1988;29:303-309.Erikson U., Hulmius G., Hemmingsson A. et al. Repeart femoral arteriography in hyperlipidemic patients, a study of progression and regression of atherosclerosis. Acta Radiol. 1988;29:303-309.Hahmann H., Bunte I., Helwig N. et al. Progression and regression of minor coronary arterial narrowings by quantitative avgiografy after fenofibrate therapy. Am J Cardiol. 1991; 67:957-961.Hahmann H., Bunte I., Helwig N. et al. Progression and regression of minor coronary arterial narrowings by quantitative avgiografy after fenofibrate therapy. Am J Cardiol. 1991; 67:957-961.McLaughlin P.R., Gladstone P., The Diabetes Atherosclerosis intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. Catheter Cardiovasc Diagn. 1998;44:249-256.McLaughlin P.R., Gladstone P., The Diabetes Atherosclerosis intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. Catheter Cardiovasc Diagn. 1998;44:249-256.Steiner G. Coronary artery disease in diabetes: results of the Diabetes Atherosclerosis Intervention Study (DAIS). Drug Benefit Trends. 2001;13 Suppl. A: S15-S21.Steiner G. Coronary artery disease in diabetes: results of the Diabetes Atherosclerosis Intervention Study (DAIS). Drug Benefit Trends. 2001;13 Suppl. A: S15-S21.Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: a randomised study. Lancet. 2001;357:905-910.Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: a randomised study. Lancet. 2001;357:905-910.Haffner S.M., Lehto S., Ronnenaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.Haffner S.M., Lehto S., Ronnenaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.Malmberg K., Yusuf S., Gerstein H.C. et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes). Registry. Circulation. 2000;102:1014-1019.Malmberg K., Yusuf S., Gerstein H.C. et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes). Registry. Circulation. 2000;102:1014-1019.Stratton I.M., Adler A.I., Neil H.A. et al. Assotiation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.Stratton I.M., Adler A.I., Neil H.A. et al. Assotiation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.Haffner S.M., Mykkanen L., Festa A. et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-980.Haffner S.M., Mykkanen L., Festa A. et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-980.Grundy S.M., Small L.D.L. Аtherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.Grundy S.M., Small L.D.L. Аtherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.Haffner S.M., Alexander CM, Cook TL et al. Reduced coronary events in simvastatintreated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analysis in the Scandinavian Survival Study. Arch Intern Med. 1999;159:2661-2667.Haffner S.M., Alexander CM, Cook TL et al. Reduced coronary events in simvastatintreated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analysis in the Scandinavian Survival Study. Arch Intern Med. 1999;159:2661-2667.Sacks FM, Pfeffer M.A., Moye L.A. et al. For the Cholesterol And Recurrent Events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.Sacks FM, Pfeffer M.A., Moye L.A. et al. For the Cholesterol And Recurrent Events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.Tonkin A.M., Colquhoun D., Emberson J. et al. Effects of pravastatin in 3 260 patients with unstable angina: results from the LIPID study. Lancet. 2000;355:1871-1875.Tonkin A.M., Colquhoun D., Emberson J. et al. Effects of pravastatin in 3 260 patients with unstable angina: results from the LIPID study. Lancet. 2000;355:1871-1875.Rubins H.B., Robins S.J., Collins D. et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med. 2002;162:2597-2604.Rubins H.B., Robins S.J., Collins D. et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med. 2002;162:2597-2604.The FIELD investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitas (the FIELD study): randomised controlled trial. Lancet. 2005:366:1849-1861.The FIELD investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitas (the FIELD study): randomised controlled trial. Lancet. 2005:366:1849-1861.Chapman M.J. Fibrates: therapeutic review. Br J Diabetes Vasc Dis. 2006;6:11-20.Chapman M.J. Fibrates: therapeutic review. Br J Diabetes Vasc Dis. 2006;6:11-20.Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994;111:161-174.Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994;111:161-174.Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1849-1889.Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1849-1889.Pedersen T.R., Faergeman O., Kastelein J.J., et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (LDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.Pedersen T.R., Faergeman O., Kastelein J.J., et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (LDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.Kastelein J.J. Оn behalf of the fenofibrate/metformin study group. Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Circulation 2005; 112 (Suppl): Abstract 3878.Kastelein J.J. Оn behalf of the fenofibrate/metformin study group. Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Circulation 2005; 112 (Suppl): Abstract 3878.
The authors declare that there are no conflicts of interest present.